215 related articles for article (PubMed ID: 24607293)
1. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
[TBL] [Abstract][Full Text] [Related]
2. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
Narula PK; Rehan HS; Unni KE; Gupta N
Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
[TBL] [Abstract][Full Text] [Related]
3. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
4. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
6. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial.
Mostafavi A; Solhi M; Mohammadi MR; Hamedi M; Keshavarzi M; Akhondzadeh S
Acta Med Iran; 2014; 52(10):734-9. PubMed ID: 25369006
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
[TBL] [Abstract][Full Text] [Related]
9. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Mostafavi SA; Solhi M; Mohammadi MR; Akhondzadeh S
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):440-444. PubMed ID: 28339282
[TBL] [Abstract][Full Text] [Related]
10. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial.
Romo-Nava F; Alvarez-Icaza González D; Fresán-Orellana A; Saracco Alvarez R; Becerra-Palars C; Moreno J; Ontiveros Uribe MP; Berlanga C; Heinze G; Buijs RM
Bipolar Disord; 2014 Jun; 16(4):410-21. PubMed ID: 24636483
[TBL] [Abstract][Full Text] [Related]
11. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.
Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257
[TBL] [Abstract][Full Text] [Related]
12. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.
Assunção SS; Ruschel SI; Rosa Lde C; Campos JA; Alves MJ; Bracco OL; de Lima MS
Braz J Psychiatry; 2006 Dec; 28(4):270-6. PubMed ID: 17242805
[TBL] [Abstract][Full Text] [Related]
13. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
Baptista T; Rangel N; El Fakih Y; Uzcátegui E; Galeazzi T; Beaulieu S; Araujo de Baptista E
Pharmacopsychiatry; 2009 Jan; 42(1):14-9. PubMed ID: 19153941
[TBL] [Abstract][Full Text] [Related]
15. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
[TBL] [Abstract][Full Text] [Related]
19. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
[TBL] [Abstract][Full Text] [Related]
20. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
